JP Morgan Chase
ITRM

JP Morgan Chase’s Iterum Therapeutics ITRM Stock Holding History

JP Morgan Chase’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$1 – 7562
2024
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 7372

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's ITRM Position: Q4 2024 in Review

JP Morgan Chase sold out of Iterum Therapeutics (ITRM) in Q4 2024, closing a stake of 1 share — an estimated $1 sold.

JP Morgan Chase first reported a position in ITRM in Q3 2024 and held it in 1 quarter. The position peaked at $1 in Q3 2024. 24 funds tracked by Wall St. Rank hold ITRM as of Q4 2024.

  • JP Morgan Chase reported no remaining Iterum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • JP Morgan Chase sold 1 Iterum Therapeutics share in Q4 2024, an estimated $1.
  • JP Morgan Chase first reported a position in Iterum Therapeutics in Q3 2024 and held it in 1 quarter.
  • JP Morgan Chase's Iterum Therapeutics position peaked at $1 in Q3 2024.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2024.

Based on JP Morgan Chase's 13F filing for Q4 2024, filed 12 Feb 2025.